で公開中です！ 詳しく見る
KODのアイコン

Kodiak Sciences
KOD

85.75 USD
-2.37
2.69%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
85.00
-0.75
0.87%
1日
-2.69%
5日間
-14.32%
1か月
161.67%
3か月
107.88%
6か月
112.2%
年初来
229.55%
1年
474.73%
5年間
-23.28%
10年間
744%
 

概要： Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

従業員数： 124

ヘルスケア バイオテクノロジー

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 40%
ニュートラル 50%
ネガティブ 10%
ニュートラル
Schaeffers Research
4 日前
11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
11 Stocks Most Likely to See a Short Squeeze Rally
ニュートラル
PRNewsWire
10 日前
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
ネガティブ
Benzinga
12 日前
Top 3 Health Care Stocks That May Collapse In Q4
As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 3 Health Care Stocks That May Collapse In Q4
ニュートラル
MarketBeat
14 日前
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
Kodiak Sciences NASDAQ: KOD reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuity outcomes.
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
ネガティブ
24/7 Wall Street
17 日前
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
ポジティブ
Zacks Investment Research
18 日前
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
ポジティブ
The Motley Fool
18 日前
Why Kodiak Sciences Skyrocketed Today
Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade.
Why Kodiak Sciences Skyrocketed Today
ニュートラル
Seeking Alpha
18 日前
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
ポジティブ
Proactive Investors
18 日前
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement.
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
ポジティブ
Benzinga
19 日前
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences Inc. (NASDAQ:KOD) on Monday released data from the Phase 3 DAYBREAK trial for patients suffering from wet age-related macular degeneration (wAMD).
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています